Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
Division of Infectious Diseases, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
Am J Nephrol. 2021;52(2):161-172. doi: 10.1159/000514234. Epub 2021 Mar 25.
Renal involvement in COVID-19 is less well characterized in settings with vigilant public health surveillance, including mass screening and early hospitalization. We assessed kidney complications among COVID-19 patients in Hong Kong, including the association with risk factors, length of hospitalization, critical presentation, and mortality.
Linked electronic records of all patients with confirmed COVID-19 from 5 major designated hospitals were extracted. Duplicated records due to interhospital transferal were removed. Primary outcome was the incidence of in-hospital acute kidney injury (AKI). Secondary outcomes were AKI-associated mortality, incident renal replacement therapy (RRT), intensive care admission, prolonged hospitalization and disease course (defined as >90th percentile of hospitalization duration [35 days] and duration from symptom onset to discharge [43 days], respectively), and change of estimated glomerular filtration rate (GFR). Patients were further stratified into being symptomatic or asymptomatic.
Patients were characterized by young age (median: 38.4, IQR: 28.4-55.8 years) and short time (median: 5, IQR: 2-9 days) from symptom onset to admission. Among the 591 patients, 22 (3.72%) developed AKI and 4 (0.68%) required RRT. The median time from symptom onset to in-hospital AKI was 15 days. AKI increased the odds of prolonged hospitalization and disease course by 2.0- and 3.5-folds, respectively. Estimated GFR 24 weeks post-discharge reduced by 7.51 and 1.06 mL/min/1.73 m2 versus baseline (upon admission) in the AKI and non-AKI groups, respectively. The incidence of AKI was comparable between asymptomatic (4.8%, n = 3/62) and symptomatic (3.7%, n = 19/519) patients.
The overall rate of AKI among COVID-19 patients in Hong Kong is low, which could be attributable to a vigilant screening program and early hospitalization. Among patients who developed in-hospital AKI, the duration of hospitalization is prolonged and kidney function impairment can persist for up to 6 months post-discharge. Mass surveillance for COVID-19 is warranted in identifying asymptomatic subjects for earlier AKI management.
在有严密公共卫生监测的环境中,包括大规模筛查和早期住院治疗,COVID-19 对肾脏的影响不太明显。我们评估了香港 COVID-19 患者的肾脏并发症,包括与危险因素、住院时间、重症表现和死亡率的关系。
从 5 家主要指定医院提取所有确诊 COVID-19 患者的电子病历。因院内转科而重复的记录已被删除。主要结局是院内急性肾损伤(AKI)的发生率。次要结局是 AKI 相关死亡率、新发肾脏替代治疗(RRT)、重症监护入院、延长住院时间和病程(分别定义为住院时间>第 90 百分位数[35 天]和症状出现至出院时间[43 天]),以及估计肾小球滤过率(GFR)的变化。患者进一步分为有症状和无症状。
患者的特点是年龄较轻(中位数:38.4,IQR:28.4-55.8 岁),从发病到入院的时间较短(中位数:5,IQR:2-9 天)。在 591 名患者中,22 名(3.72%)发生 AKI,4 名(0.68%)需要 RRT。从症状出现到院内 AKI 的中位时间为 15 天。AKI 使延长住院时间和病程的几率分别增加了 2.0 倍和 3.5 倍。与基线(入院时)相比,出院后 24 周时,AKI 组和非 AKI 组的估计肾小球滤过率分别下降了 7.51 和 1.06 mL/min/1.73 m2。在无症状(4.8%,n=3/62)和有症状(3.7%,n=19/519)患者中,AKI 的发生率无差异。
香港 COVID-19 患者的 AKI 总发生率较低,这可能归因于严密的筛查计划和早期住院治疗。在发生院内 AKI 的患者中,住院时间延长,肾功能损害可持续 6 个月以上。需要对 COVID-19 进行大规模监测,以发现无症状患者并及早进行 AKI 管理。